HYPERTHERMIA FOR THE TREATMENT OF PATIENTS WITH MALIGNANT GERM-CELL TUMORS - A PHASE-I PHASE-II STUDY IN 10 CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY TUMORS/
R. Wessalowski et al., HYPERTHERMIA FOR THE TREATMENT OF PATIENTS WITH MALIGNANT GERM-CELL TUMORS - A PHASE-I PHASE-II STUDY IN 10 CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY TUMORS/, Cancer, 82(4), 1998, pp. 793-800
BACKGROUND. Extracranial nontesticular germ cell tumors (GCTs) are rar
e malignancies in children and adolescents. Cisplatin-containing regim
ens and complete tumor resection are important determinants for a favo
rable outcome; however, patients with recurrent tumors that cannot be
eradicated by surgical procedures and chemotherapy have a poor prognos
is. Noninvasive electromagnetic technologies for superficial and regio
nal deep hyperthermia (RHT) are under investigation to enhance local t
umor control in various malignancies. The objectives of this Phase I/I
I study were to examine 1) whether RHT can be used in combination with
platinum-based chemotherapy with acceptable toxicity in children and
adolescents and 2) whether this combined regimen can induce objective
tumor response in patients with malignant nontesticular GCT that persi
sted or recurred locoregionally after validated, intensive, cisplatin-
based chemotherapy +/- surgery as unsuccessful first-line treatment. M
ETHODS. The authors studied the effects of RHT induced by electromagne
tic waves in combination with platinum-based chemotherapy in ten child
ren and adolescents with recurrent or refractory GCTs. RESULTS. Seven
of ten patients with recurrent or refractory GCTs had objective respon
ses. Of these, two patients had a partial response and five patients h
ad a complete response. CONCLUSIONS. The results of the current study
found that combined RHT and platinum-based chemotherapy can be used in
children and adolescents. This regimen was found to induce objective
tumor response in 70% of study patients with recurrent or refractory G
CTs. The results thus far are encouraging and the study has been exten
ded to patients with a poor response to first-line treatment. (C) 1998
American Cancer Society.